A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers
A Bioequivalence Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Administration of TELMIONE PLUS TAB. 80/12.5mg and MICARDIS PLUS TAB. 80/12.5mg in Healthy Adult Volunteers
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Chungcheongbuk-do
-
Cheongju-si、Chungcheongbuk-do、大韓民国、28644
- Chungbuk National University Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Healthy adult volunteers aged ≥ 19 years at screening
- Body weight ≥ 50kg and Body mass index (BMI) in the range of 18.0 and 30.0 kg/㎡
- Subjects who do not have congenital or chronic diseases requiring treatment and have no pathological symptoms or findings as a result of physical examination
- Determined by the investigator to be eligible for study participation based on the results of screening tests (clinical laboratory tests, vital signs, physical examination, 12-lead ECG) conducted according to the IP characteristics
- Subjects who decided to participate in the study and signed informed consent form voluntarily after receiving detailed explanation of the study and fully understanding
Exclusion Criteria:
- Subjects with a presence and a history of clinically significant hepatic, renal, neurology, psychiatric, pulmonary, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal disease
- Pregnant(positive urine HCG) or breastfeeding women if female
- Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- Subjects with a presence and a history of surgery or gastrointestinal diseases which might significantly change absorption of medicines
- Subjects with hypersensitivity or a history of clinically significant hyper sensitivity to ingredients with IPs, excipients, other drugs including sulfonamide and renin-angiotensin class
Subjects with the following results in clinical laboratory tests
- AST/ALT/ALP/γ-GTP/Bilirubin total > UNL (upper normal limit) × 2
- Creatinine in plasma which is outside the accepted normal range or eGFR calculated by MDRD < 60 mL/min/1.73 ㎡
- CK > UNL × 2
- Subjects with a history of drug abuse or positive to drug abuse at urine drug screening test
- Subjects with systolic blood pressure (SBP) ≥ 140 mmHg or ≤ 90 mmHg, diastolic blood pressure (DBP) ≥ 100 mmHg or ≤ 60 mmHg, or pulse rate (PR) ≤ 40 bpm or ≥ 100 bpm on vital signs measured in sitting position after taking a rest for at least 3 minutes during screening test
Subjects with clinically significant opinions including the following results in 12-lead ECG test during screening test
- QTc > 450 ms
- PR interval > 200 ms
- QRS duration > 120 ms
- Subjects who have an abnormal diet that can affect ADME of drugs or consume foods that can affect drug metabolism
- Subjects who have taken any prescription drugs or herbal medicine within 2 weeks prior to the 1st IP administration, or any over-the-counter (OTC) drug, health functional food or vitamin preparation within 10 days to the 1st IP administration (However, can participate in the study if otherwise eligible in the judgment of the investigator)
- Subjects who have taken the drug which can induce or inhibit drug metabolism enzyme within 1 month prior to the 1st IP administration
- Subjects who have participated in any other clinical study or bioequivalnece study within 6 months prior to the 1st IP administration(However, the criterion for termination of participation in other clinical study or bioequivalence study is the last administration date, and the next day is counted as one day.)
- Subjects who have donated whole blood within 2 months prior to the 1st IP administration or have donated blood components or received transfusion within 1 month prior to the 1st IP administration
Subject who have continued drink of alcohol (> 21 units/week, 1 unit = 10 g = 12.5 mL of pure alcohol) within 6 months prior to the 1st IP administration or are unable to stop drinking from the time of signing the informed consent form to post study visit
- alcohol (g) = intake volume(mL) × level(%) × 0.8
- Subject who have a history of excessive smoking (> 10 cigarettes/day) within 3 months prior to the 1st IP administration and unable to stop smoking from 24 hours before the administration at each period to the last sampling time at each period
- Subjects who take or are unable to stop foods containing grapefruit from 48 hours before the 1st IP administration to post study visit
- Subject who take or are unable to stop foods containing caffeine(coffee, green tea, black tee, soda, coffee-flavored milk, nutritive tonic drink) from 24 hours before the administration at each period to the last sampling time at each period
- Subjects who have exercised vigorously exceeding the level of daily life during the period from 48 hours before the 1st administration to post study visit, or who are unable to stop vigorous exercise
- Subjects or their spouse or partner who are not using an approved method of contraception or even if are not planning to become pregnant (e.g., contraceptive administration and implantation, intrauterine device, Those who are not using procedures (vasectomy, tubal ligation, etc.) from the time of written consent of the subject until two weeks after the last bioequivalence study drug administration date
- Subjects who have determined that the investigator is unsuitable to participate in the bioequivalence test due to reasons other than the above selection/exclusion criteria
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:シーケンスA
TRTR
|
Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
|
|
実験的:シーケンスB
RTRT
|
Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
テルミサルタンのCmax
時間枠:最大72時間
|
最大72時間
|
|
テルミサルタンのAUClast
時間枠:最大72時間
|
最大72時間
|
|
Cmax of hydrochlorothiazide
時間枠:Up to 72 hours
|
Up to 72 hours
|
|
AUClast of hydrochlorothiazide
時間枠:Up to 72 hours
|
Up to 72 hours
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
テルミサルタンのTmax
時間枠:最大72時間
|
最大72時間
|
|
テルミサルタンのAUCinf
時間枠:最大72時間
|
最大72時間
|
|
テルミサルタンのt1/2
時間枠:最大72時間
|
最大72時間
|
|
テルミサルタンのCL/F
時間枠:最大72時間
|
最大72時間
|
|
テルミサルタンのVd/F
時間枠:最大72時間
|
最大72時間
|
|
Tmax of hydrochlorothiazide
時間枠:Up to 72 hours
|
Up to 72 hours
|
|
AUCinf of hydrochlorothiazide
時間枠:Up to 72 hours
|
Up to 72 hours
|
|
t1/2 of hydrochlorothiazide
時間枠:Up to 72 hours
|
Up to 72 hours
|
|
CL/F of hydrochlorothiazide
時間枠:Up to 72 hours
|
Up to 72 hours
|
|
Vd/F of hydrochlorothiazide
時間枠:Up to 72 hours
|
Up to 72 hours
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- IN_TMP_101
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。